Platinum Investment Management Ltd. Acquires 45,363 Shares of Immatics (NASDAQ:IMTX)

Platinum Investment Management Ltd. raised its holdings in Immatics (NASDAQ:IMTXFree Report) by 16.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 313,574 shares of the company’s stock after purchasing an additional 45,363 shares during the quarter. Platinum Investment Management Ltd. owned approximately 0.37% of Immatics worth $3,302,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC increased its holdings in Immatics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock valued at $121,000 after purchasing an additional 2,916 shares during the last quarter. Jump Financial LLC acquired a new position in Immatics in the third quarter valued at about $469,000. Trexquant Investment LP grew its stake in Immatics by 4.2% in the fourth quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock valued at $471,000 after acquiring an additional 1,801 shares during the period. Walleye Capital LLC acquired a new position in Immatics in the third quarter valued at about $1,318,000. Finally, TD Asset Management Inc grew its stake in Immatics by 14.9% in the fourth quarter. TD Asset Management Inc now owns 227,118 shares of the company’s stock valued at $2,392,000 after acquiring an additional 29,400 shares during the period. Institutional investors own 64.41% of the company’s stock.

Immatics Stock Performance

NASDAQ:IMTX traded down $0.33 on Friday, reaching $13.16. The company’s stock had a trading volume of 445,407 shares, compared to its average volume of 806,000. The firm has a market cap of $1.11 billion, a PE ratio of -12.42 and a beta of 0.73. The business’s 50-day moving average price is $10.93 and its two-hundred day moving average price is $10.95. Immatics has a 1-year low of $7.15 and a 1-year high of $13.77.

Immatics (NASDAQ:IMTXGet Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.70. The company had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $17.76 million. Immatics had a negative return on equity of 29.36% and a negative net margin of 107.80%. As a group, sell-side analysts expect that Immatics will post -1.26 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Mizuho boosted their target price on Immatics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 16th.

Get Our Latest Report on Immatics

Immatics Profile

(Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Featured Stories

Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics (NASDAQ:IMTXFree Report).

Institutional Ownership by Quarter for Immatics (NASDAQ:IMTX)

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.